J. Craig Hartman

J. Craig Hartman has had a varied work experience since 2016. J. Craig began their career as the VP Preclinical Development for Revivo Therapeutics in 2016, and then moved to ARCA biopharma, Inc. in 2017 in a consulting role. J. Craig also consulted for The Ohio State University in 2017, and then became the VP Preclinical Development for MDI Therapeutics, Inc. in 2018. In 2019, they became a consultant for Perfuse Therapeutics, CYLERUS, INC., and Grant Reviewer for Inspiralia. In 2020, they became a consultant for Freyr Solutions and MILLENDO THERAPEUTICS, and an Advisor for AdvisoryCloud.

J. Craig Hartman obtained a BS in Biology and Chemistry from Purdue University between 1973 and 1977. J. Craig then went on to receive a Ph.D. in Pharmacology and Toxicology from the Medical College of Wisconsin between 1986 and 1990.